| 摘要 |
The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amou nt of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxa mic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, a nd a second amount of one or more anti-cancer agents, including Bortezomib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HD AC inhibitor and the anti-cancer agent may be additive or synergistic.</SDOA B>
|
